Aleniglipron
GSBR-1290
PHASE2
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaCVRM
Peak Sales Est$5000M
Formulations[{"id":"alen-oral-1","route":"ORAL","device":"Tablet","setting":"PATIENT_SELF","duration":null,"freq
Mechanism: Oral GLP-1 receptor agonist
Expert: Orally bioavailable, biased small molecule agonist of the glucagon-like peptide-1 receptor (GLP-1R) that preferentially activates G-protein signaling over β-arrestin recruitment, potentially improving tolerability while maintaining efficacy.
Everyday: A pill that mimics a natural gut hormone (GLP-1) to reduce appetite and help with weight loss, similar to injectable drugs like Ozempic but taken orally.
Targets: ["GLP-1R"]
Programs (2)
| Indication | Stage | Key Study | Regional Status |
|---|
| T2D + Obesity | PHASE2 | ACCESS-T2DM | [] |
| Obesity | PHASE2 | ACCESS / ACCESS II | [] |
Upcoming Catalysts (3)
Aleniglipron - Obesity - FDA Type B EoP2 Meeting
H1 2026
Aleniglipron - Obesity - Ph3 - Start
Mid-2026
Aleniglipron - ACCESS Full Data - Medical Meeting
2026
Notes
Lead asset. Biased GLP-1 receptor agonist preferentially activating G-protein signaling. Phase 2b ACCESS showed 11.3% weight loss at 120mg, 15.3% at 240mg (36 weeks). Titration from 2.5mg to target dose. Phase 3 initiation expected mid-2026 pending FDA Type B meeting.
Data from Supabase · Updated 2026-03-24